The observed association of GCNT1 expression with CLL prognosis is incongruent with data reported for solid tumors (e.g., bladder and prostate cancers), in which high expression of GCNT1 was associated with poor prognosis, presumably through the protection of tumors from NK cells (56–58). This evidence concerns the gene GCNT1 and prostate carcinoma.